Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

NCT02254551 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Safety lead-in data did not support continuation of study.

Conditions

Multiple Myeloma

Interventions

DRUG: LDE225
DRUG: Bortezomib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]